CALCA and Headache: However, the elevated RORs for CGRP monoclonal antibodies like eptinezumab and galcanezumab may reflect indication bias, a known limitation of FAERS where drugs prescribed for headache-related conditions over-represent such reports, as noted by Musialowicz et al. (16).